Overview
Acute bacterial and viral infections are difficult to diagnose; as many as half of all antibiotics are prescribed inappropriately. Further, some infections lead to sepsis, defined as a dysregulated host response to infections. However, approximately 70% of infections in hospital inpatients are missed by the gold standard (blood culture) since most infections do not result in bacteremia. Infections and sepsis are hard to diagnose, and thus hard to treat.

Using our custom informatics pipeline, we have derived diagnostic gene sets and algorithms that can diagnose the presence, type, and severity of acute infections. Improved diagnosis of infections could decrease hospital/ICU length of stay, improve outcomes, and reduce unnecessary antibiotic administration. We are currently developing the test into a rapid whole blood-based diagnostic for clinical use. Applications are imagined in the clinic, ED, ICU, and in post-surgical care.

Results

**HostDx™ Sepsis**
- Multiplex quantitative gene expression
- Rapid TAT (~60 min)
- Sample-to-answer, moderate complexity
- Device/manufacturing partnerships

**Example Inpatient Readout:** LR + numeric score

<table>
<thead>
<tr>
<th>Bacterial Infection</th>
<th>Viral Infection</th>
<th>30-Day Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low (0.1)</td>
<td>Low (0.1)</td>
<td>Low (0.1)</td>
</tr>
<tr>
<td>Low-Med (0.3)</td>
<td>Low-Med (0.4)</td>
<td>Low-Med (0.25)</td>
</tr>
<tr>
<td>Moderate (1.1)</td>
<td>Moderate (1.4)</td>
<td>Moderate (1.8)</td>
</tr>
<tr>
<td>High (5.0)</td>
<td>High (8.0)</td>
<td>High (4.5)</td>
</tr>
</tbody>
</table>

**Band distribution vs. prevalence @ AUC = 0.85**

**References**


Acknowledgments

The authors wish to thank their numerous collaborators and co-authors, and the employees of Inflammatix.

This research was developed with funding from the Defense Advanced Research Projects Agency (DARPA). The views, opinions and/or findings expressed are those of the author(s) and should not be interpreted as reflecting the official views or policies of the Department of Defense or the U.S. Government.

Learn more at www.inflammatix.com. Follow us on Twitter @Inflammatix_Inc. Inflammatix and HostDx are marks of Inflammatix, Inc. in the United States and other countries.